

01-24-05

JFW



Application No. (if known): 10/823,396

Attorney Docket No.: 05986/100M724-US1

Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. in an envelope addressed to:

EV 329021433 - us

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on January 21, 2005
Date

b.w. Lee

Signature

B.w. LEE

Typed or printed name of person signing Certificate

@@@
Registration Number, if applicable

(212) 527-7700
Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Transmittal (1 page)
Information Disclosure Statement (2 pages)
IDS (Citation) by Applicant (3 pages) along with 35 References
Return Receipt Postcard

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission	7	Application Number	10/823,396
		Filing Date	April 12, 2004
		First Named Inventor	Marcus B. Jones
		Art Unit	1632
		Examiner Name	Not Yet Assigned

7

Attorney Docket Number

05986/100M724-US1

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	36 References
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	Certificate of Express Mailing
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	Return Receipt Postcard
<input type="checkbox"/> Reply to Missing Parts/ Incomplete Application	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53		
	Remarks	

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	DARBY & DARBY P.C.		
Signature			
Printed name	S. Peter Ludwig		
Date	January 21, 2005	Reg. No.	25,351



Docket No.: 05986/100M724-US1
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Marcus B. Jones et al.

Application No.: 10/823,396

Confirmation No.: 3661

Filed: April 12, 2004

Art Unit: 1632

For: B. ANTHRACIS PREVENTION AND
TREATMENT; MUTANT B. ANTHRACIS
LACKING LUXS ACTIVITY AND
FURANONE INHIBITION OF GROWTH,
AI-2 QUORUM SENSING, AND TOXIN
PRODUCTION

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

A copy of each document on the PTO/SB/08 is attached.

A concise explanation of relevance of the items listed on form PTO/SB/08 is given for only non-English language listed items.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.


The Commissioner is authorized to charge any deficiency of up to \$300.00 or credit any excess in this fee to Deposit Account No. 04-0100.

Dated: January 21, 2005

Respectfully submitted,

By

S. Peter Ludwig


Registration No.: 25,351
DARBY & DARBY P.C.
P.O. Box 5257
New York, New York 10150-5257
(212) 527-7700
(212) 753-6237 (Fax)
Attorneys/Agents For Applicant



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
				Application Number	10/823,396
				Filing Date	April 12, 2004
				First Named Inventor	Marcus B. Jones
				Art Unit	1632
				Examiner Name	Not Yet Assigned
Sheet	1	of	3	Attorney Docket Number	05986/100M724-US1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)			
					T ⁶

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	CA	Adjei, et al. Pharmaceutical Research 1990; 7:565-569 and 63:135-144 (leuprolide acetate), "Pulmonary delivery of peptide drugs: effect of particle size on bioavailability of leuprolide acetate in healthy male volunteers."###			
	CB	Bassler, Wright and Silverman. Mol. Microbiol. 1994; 13:273-286, "Multiple signaling systems controlling expression of luminescence in Vibrio harveyi: sequence and function of genes encoding a second sensory pathway."			
	CC	Benoist & Chambon, Nature 1981; 290:304-310I, "Sequence requirements of the SV40 early promotor region."			
	CD	Braquet, et al. J. Cardiovascular Pharmacology 1989;13 (sup5): 143-146 (endothelin-1) "Effect of endothelin-1 on blood pressure and bronchopulmonary system of the guinea pig."			
	CE	Brinster RL, et al., Nature 1982; 296:39-42, "Regulation of metallothionein--thymidine kinase fusion plasmids injected into mouse eggs."			
	CF	Chang TK et al., (1993) Cancer Res. 53:1043-1050, "Differential activation of cyclophosphamide and ifosfamide by cytochromes P-450 2B and 3A in human liver microsomes."			
	CG	Chen et al., Nature 2001; 415:545-549, Chen, X., S. Schauder, N. Potier, A. Dorsseelaer, I. Pelczar, B. Bassler, and F. M. Hughson. 2001. "Structural identification of a bacterial quorum-sensing signal containing boron." Nature 415:545-549			
	CH	Cote et al., Proc. Natl. Acad. Sci. USA 1983;80:2026-2030, "Generation of Human Monoclonal Antibodies Reactive with Cellular Antigens."			
	CI	Debs RJ, et al. J. Immunol. 1988; 140:3482-3488 (interferon- and tumor necrosis factor) "Lung-specific delivery of cytokines induces sustained pulmonary and systemic immunomodulation in rats."			
	CJ	Greenberg, Hastings and Ullitzur. Arch. Microbiol. 1979; 120:87-91, "Not found on Medline, please provide reference."			
	CK	Greener, et al., Strategies in Mol. Biol. 1995 7:32, "Not found on Medline, please provide reference."			
	CL	Guerot-Fleury, A., et al. Gene. 1995;167:335-336, "Antibiotic resistance cassettes for Bacillus			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Substitute for form 1449A/B/PTO				Complete if Known	
				Application Number	10/823,396
				Filing Date	April 12, 2004
				First Named Inventor	Marcus B. Jones
				Art Unit	1632
				Examiner Name	Not Yet Assigned
Sheet	2	of	3	Attorney Docket Number	05986/100M724-US1

		reference."	
	CM	Guerot-Fleury, A., et al. Gene. 1995;167:335-336, "Antibiotic resistance cassettes for <i>Bacillus subtilis</i> ."	
	CN	Hermes et al., Proc. Natl. Acad. Sci. USA 1990;87:696-700, "Searching Sequence Space by Definably Random Mutagenesis: Improving the Catalytic Potency of an Enzyme."	
	CO	Hood et al., Immunology, Second Ed., 1984, Benjamin/Cummings: Menlo Park, California, p. 384, Book	
	CP	Hubbard, et al. (1989) Annals of Internal Medicine, Vol. III, pp. 206-212 (1-antitrypsin), Book chapter NOTE: Can be provided upon request.	
	CQ	Huse WD et al., Science 1989; 246:1275-1281, "Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda."	
	CR	Bassler, Wright and Silverman. Mol. Microbiol. 1994; 13:273-286, "Multiple signaling systems controlling expression of luminescence in <i>Vibrio harveyi</i> : sequence and function of genes encoding a second sensory pathway."	
	CS	Jernigan JA, et al., Emer. Inf. Dis. 2001;7:933-933, "Bioterrorism-related inhalation anthrax: the first 10 cases reported in the United States."	
	CT	Kohler G & Milstein C, Nature 1975; 256:495-497, "Continuous cultures of fused cells secreting antibody of predefined specificity."	
	CU	Kozbor et al., Immunology Today 1983;4:72	
	CV	Loeffler DA et al (1992) Cytom. 13: 169-174, "Analysis of distribution of tumor-and preneoplasia-infiltrating lymphocytes using simultaneous Hoechst 33342 labeling and immunophenotyping."	
	CW	Marshall, K. In: Modern Pharmaceutics Edited by G.S. Bunker and C.T. Rhodes, Chapter 10, 1979 Book, NOTE: Can be provided upon request.	
	CX	Mock, M., and A. Fouet. Annu. Rev. Microbiol 2001;55:647-671Mock, M., and A. Fouet. 2001, "Anthrax. Annu. Rev. Microbiol. 55:647-671"	
	CY	Morrison et al., J. Bacteriol. 1984; 159:870, "Isolation of transformation-deficient <i>Streptococcus pneumoniae</i> mutants defective in control of competence, using insertion-duplication mutagenesis with the erythromycin resistance determinant of pAM beta 1."	
	CZ	Neuberger et al., Nature 1984;312:604-608, "Recombinant antibodies possessing novel effector functions"	
	CA1	Nielsen PE et al., Science 1991, 254:1497, "Sequence-selective recognition of DNA by strand displacement with thymine-substituted polyamide."	
	CB1	Provinciali M, et al., (1992) J. Immunol. Meth. 155:19-24, "Optimization of cytotoxic assay by target cell retention of the fluorescent dye carboxyfluorescein diacetate (CFDA) and comparison with conventional 51CR release assay."	
	CC1	Ren, D. et al., Environ. Microbiol. 2001;3:731-736, "Inhibition of biofilm formation and swarming of <i>Escherichia coli</i> by (5Z)-4-bromo-5-(bromomethylene)-3-butyl-2(5H)-furanone."	
	CD1	Ren, D. et al., Let. Appl. Microbiol. 2002;34:293-299, "Inhibition of biofilm formation and swarming of <i>Bacillus subtilis</i> by (5Z)-4-bromo-5-(bromomethylene)-3-butyl-2(5H)-furanone."	
	CE1	Rivoltini L et al., (1992) Can. Immunol. Immunother. 34: 241-251, "Phenotypic and functional analysis of lymphocytes infiltrating paediatric tumours, with a characterization of the tumour phenotype."	
	CF1	Scientific American 1980;242:74-94	
	CG1	Sirard, Mock and Foeut. J. Bacteriol. 1994;176:5188-92, "The three <i>Bacillus anthracis</i> toxin genes are coordinately regulated by bicarbonate and temperature."	
	CH1	Takeda S et al., Nature 1985;314:452-454, "Construction of chimaeric processed immunoglobulin genes containing mouse variable and human constant region sequences."	
	CI1	Villa-Komaroff L et al., proc. Natl. Acad. Sci. USA 1978;75:3727-3731, "A Bacterial Clone Synthesizing Proinsulin."	
	CJ1	Vollenweider I et al., (1992) J. Immunol. Meth. 149:133-135, "Comparison of four DNA staining	
Examiner Signature		Date Considered	

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				<i>Complete if Known</i>	
				Application Number	10/823,396
				Filing Date	April 12, 2004
				First Named Inventor	Marcus B. Jones
				Art Unit	1632
				Examiner Name	Not Yet Assigned
Sheet	3	of	3	Attorney Docket Number	05986/100M724-US1

		fluorescence dyes for measuring cell proliferation of lymphokine-activated killer (LAK) cells."	
	CK1	Wagner, et al., Proc. Natl. Acad. Sci. USA 1981; 78:1441-1445,	
	CL1	Yamamoto T, et al., Cell 1980;22:787-797, "Identification of a functional promoter in the long terminal repeat of Rous sarcoma virus."	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--